Entrada Therapeutics (TRDA) announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. Since August 2024, Dr. Radhakrishnan has served as Executive Partner at Sofinnova Investments, a European venture capital firm focused on life sciences
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRDA:
- Buy Rating for Entrada Therapeutics: Strategic Positioning and Regulatory Advances in Exon-Skipping Therapeutics
- Entrada Therapeutics receives authorization from in EU to start ELEVATE-45-201
- Entrada Therapeutics price target lowered to $21 from $23 at Roth Capital
- Entrada Therapeutics: Strategic Advancements in DMD Pipeline Drive Buy Rating
- Entrada Therapeutics reports Q1 EPS (42c), consensus (77c)